HBV Capsid inhibitor 3711

CAS No. 2041072-40-4

HBV Capsid inhibitor 3711 ( Compound 3711 )

Catalog No. M13173 CAS No. 2041072-40-4

HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    HBV Capsid inhibitor 3711
  • Note
    Research use only, not for human use.
  • Brief Description
    HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor.
  • Description
    HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor, inhibits hepatitis B virus replication by inducing genome-free capsid formation; decreases extracellular HBV DNA levels and intracellular DNA levels with EC50 of 1.5 and 1.9 uM in a cell model system; shows sensitivity against both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant; decreases levels of HBV DNA contained in both secreted enveloped virion and naked virus particles in supernatant, interferes with capsid formation of the core protein (Cp) assembly domain.
  • Synonyms
    Compound 3711
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2041072-40-4
  • Formula Weight
    367.83
  • Molecular Formula
    C20H18ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N-(4-(1-(4-chlorobenzyl)-5-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Feng S, et al. ACS Infect Dis. 2018 Mar 9;4(3):257-277.
2. Wang YJ, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):7061-72.
molnova catalog
related products
  • RG7834

    RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).

  • RO6889678

    RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.

  • Besifovir

    Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).